Oramed Pharmaceuticals reports $65 million net income for nine months ended September 2025
Oramed Pharmaceuticals Inc. reported a pre-tax net income of $65 million for the nine months ended September 30, 2025, reversing a net loss of $6.1 million from the previous year. Basic earnings per share were $1.30, and diluted earnings per share were $1.26. Total assets increased by 42% year-over-year. The company also completed a $100 million principal repayment from Scilex and reported unrealized gains from equity holdings.
Oramed Pharmaceuticals Inc. reported unaudited financial results for the nine months ended September 30, 2025. The company recorded a pre-tax net income of $65.0 million, compared to a net loss of $6.1 million for the same period last year. Basic earnings per share were $1.30 and diluted earnings per share were $1.26. Total assets rose by 42% year-over-year, from $155.3 million to $220.5 million. Research and development expenses decreased from $4.9 million to $4.4 million, while general and administrative expenses increased from $4.3 million to $5.0 million. During the period, Oramed completed a full $100 million principal repayment from Scilex and reported substantial unrealized gains from its equity holdings in Alpha Tau Medical Ltd. and other investments. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN25981) on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
